Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
March 14, 2023 16:05 ET
|
Arbutus Biopharma Corporation
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14,...
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
March 02, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for...
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
February 16, 2023 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Participate in Three Upcoming Investor Conferences
February 06, 2023 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces Resignation of Board Member
January 27, 2023 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
January 05, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into...
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
December 13, 2022 07:30 ET
|
Arbutus Biopharma Corporation
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE...
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 07:30 ET
|
Arbutus Biopharma Corporation
Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after...
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2022 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
November 01, 2022 16:01 ET
|
Arbutus Biopharma Corporation
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in...